Not Yet Recruiting
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
NCT07283640
- Conditions
- Blinatumomab, Hematologic Diseases, Hemic and Lymphatic Diseases, +12 more
- Locations
-
- MD Anderson Cancer Houston, Texas, United States